Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

Rhea-AI Summary

Achieve Life Sciences (Nasdaq: ACHV) will host in-person one-on-one meetings during the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, Jan 12–15, 2026. CEO Rick Stewart and senior management will overview Achieve's late-stage cytisinicline program for smoking and vaping cessation and discuss plans for the upcoming year.

Investors may schedule meetings by contacting Investor Relations at ir@achievelifesciences.com.

Key Figures

Conference edition 44th Annual J.P. Morgan Healthcare Conference referenced in the announcement

Meeting dates January 12–15, 2026 In-person one-on-one meetings during the J.P. Morgan Healthcare week

Market Reality Check

$5.19 Last Close

Volume Volume 570,633 is slightly below the 20-day average of 610,545 (relative volume 0.93x). normal

Technical Shares at $4.38 are trading above the 200-day MA of $3.22 and 138.04% above the 52-week low.

Peers on Argus

Peers show mixed moves: ACOG up 8.7%, CHRS up 0.72%, while ELDN and MIST are down 1.81% and 5.98%. This contrasts with ACHV’s -2.45% move, suggesting stock-specific dynamics rather than a unified sector trend.

Common Catalyst Only one peer (NVCT) reported same-day clinical news, indicating no broad conference- or sector-wide catalyst.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 08	Inducement awards	Neutral	-0.2%	New hire stock option grants under the 2024 Equity Inducement Plan.
Nov 06	Earnings & NDA update	Positive	-3.9%	Q3 2025 results plus FDA acceptance of cytisinicline NDA and PDUFA date.
Nov 03	Clinical milestones	Positive	-0.2%	ORCA-OL long-term safety milestones and favorable DSMC safety review.
Oct 29	Earnings call notice	Neutral	+3.6%	Announcement of timing for Q3 2025 results call and webcast.
Oct 20	Executive appointment	Positive	+19.1%	Appointment of a Chief Legal Officer to support regulatory and governance needs.

Pattern Detected

Recent ACHV news shows positive regulatory and clinical milestones sometimes met with negative price reactions, while management and corporate updates have drawn more supportive responses.

Recent Company History

Over the last few months, Achieve Life Sciences has reported several milestones around cytisinicline and corporate development. On Oct 20, 2025, it appointed a new Chief Legal Officer, which saw a 19.05% price gain. Subsequent updates, including completion of key cytisinicline safety milestones and Q3 2025 results with FDA NDA acceptance and a June 20, 2026 PDUFA date, were followed by modest declines. The current conference-related announcement fits into ongoing investor outreach as the program advances toward potential regulatory outcomes.

Market Pulse Summary

This announcement centers on Achieve’s plan to host one-on-one meetings during the J.P. Morgan Healthcare Conference, giving management a platform to outline its late-stage cytisinicline program and upcoming year plans. In context of recent regulatory and clinical milestones and disclosed financing needs, investors may watch how clearly the company articulates its path toward the June 20, 2026 PDUFA date, commercialization strategy, and capital requirements for launching a smoking and vaping cessation therapy.

Key Terms

cytisinicline medical

"overview of Achieve's late-stage cytisinicline program for smoking and vaping"

Cytisinicline is a plant-derived medicine that gently activates the same brain receptors nicotine does to reduce cravings and withdrawal, used primarily to help people stop smoking. It matters to investors because trial results, regulatory approvals, and pricing determine whether it can become a low-cost, widely adopted treatment in the large smoking-cessation market—similar to how a cheaper, effective alternative to a popular product can reshape demand.

nicotine dependence medical

"commercialization of cytisinicline as a treatment for nicotine dependence"

Nicotine dependence is a medical condition where a person feels a strong physical and psychological need to use nicotine and has difficulty stopping even when it harms their health. Investors should care because the size and persistence of this habit drive demand for cessation products, influence regulatory and labeling decisions, and can create legal or public-health pressures on companies; think of it like a habit so ingrained it shapes an entire market for solutions and oversight.

vaping cessation medical

"late-stage cytisinicline program for smoking and vaping cessation"

Vaping cessation is the process, programs, or products intended to help people stop using e‑cigarettes and other vaping devices, similar to smoking‑quit aides or counseling that help break a habit. It matters to investors because shifts toward quitting tools, regulations, or declining vaping rates can change demand, create new markets for therapies and devices, alter legal and regulatory risks, and affect revenue for companies in tobacco, healthcare and consumer sectors.

AI-generated analysis. Not financial advice.

SEATTLE and VANCOUVER, BC, Dec. 17, 2025 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, announced today that the company will be hosting in-person one-on-one meetings coinciding with the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026.

Rick Stewart, Chief Executive Officer of Achieve Life Sciences, along with other members of senior management, will provide an overview of Achieve's late-stage cytisinicline program for smoking and vaping cessation and discuss plans for the upcoming year.

To schedule a one-on-one meeting with the company, please contact Investor Relations at ir@achievelifesciences.com.

About Achieve Life Sciences, Inc. 
Achieve Life Sciences is a late-stage specialty pharmaceutical company committed to addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. In September 2025, the company announced that its New Drug Application, submitted to the U.S. Food and Drug Administration (FDA) in June 2025, had been accepted for review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of June 20, 2026. The NDA is for cytisinicline to be used as a treatment of nicotine dependence for smoking cessation in adults, based on two successfully completed Phase 3 studies and its open-label safety study. Additionally, the company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication.

About Cytisinicline
There are approximately 29 million adults in the United States who smoke combustible cigarettes.¹ Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.^2,3 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.³

In addition, there are approximately 17 million adults in the United States who use e-cigarettes, also known as vaping.⁴ In 2024, approximately 1.6 million middle and high school students in the United States reported using e-cigarettes.⁵ There are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation. FDA has awarded the Commissioner's National Priority Voucher for e-cigarette or vaping cessation and granted Breakthrough Therapy designation to address this critical need. 

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products. Cytisinicline is an investigational product candidate being developed as a treatment of nicotine dependence for smoking cessation and has not been approved by the FDA for any indication in the United States.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements Achieve makes regarding its expectation of market conditions and use of proceeds, the timing and nature of cytisinicline clinical development and regulatory review and approval, data results and commercialization activities, the potential market size for cytisinicline, the potential benefits, efficacy, safety and tolerability of cytisinicline, the development and effectiveness of new treatments, and the successful commercialization of cytisinicline. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Achieve Contact
Nicole Jones
VP, Strategic Communications and Stakeholder Relations
ir@achievelifesciences.com
425-686-1510

References
¹VanFrank B, Malarcher A, Cornelius ME, Schecter A, Jamal A, Tynan M. Adult Smoking Cessation — United States, 2022. MMWR Morb Mortal Wkly Rep 2024;73:633–641.
²World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.
³U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.
⁴Vahratian A, Briones EM, Jamal A, Marynak KL. Electronic cigarette use among adults in the United States, 2019–2023. NCHS Data Brief, no 524. Hyattsville, MD: National Center for Health Statistics. 2025. DOI: https://dx.doi.org/ 10.15620/cdc/174583.
⁵Jamal A, Park-Lee E, Birdsey J, et al. Tobacco Product Use Among Middle and High School Students — National Youth Tobacco Survey, United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:917–924.

View original content to download multimedia:https://www.prnewswire.com/news-releases/achieve-life-sciences-to-host-meetings-during-the-jp-morgan-healthcare-conference-week-302645164.html

SOURCE Achieve Life Sciences

FAQ

When will Achieve Life Sciences (ACHV) meet at the J.P. Morgan Healthcare Conference?

Achieve will host one-on-one meetings during Jan 12–15, 2026 at the 44th Annual J.P. Morgan Healthcare Conference.

Who will represent Achieve Life Sciences (ACHV) at the January 2026 meetings?

Rick Stewart, CEO, and other senior management will provide an overview of the company's program.

What topic will Achieve Life Sciences (ACHV) discuss at the J.P. Morgan meetings?

Management will discuss the late-stage cytisinicline program for smoking and vaping cessation and plans for the coming year.

How can investors schedule a one-on-one meeting with Achieve Life Sciences (ACHV)?

To schedule a meeting, contact Investor Relations at ir@achievelifesciences.com.

Is Achieve Life Sciences (ACHV) presenting publicly at the J.P. Morgan Healthcare Conference?

The company announced in-person one-on-one meetings; no public presentation details were provided.